New DOT drug testing requirements for 2026: what changed, and what didn't

New DOT drug testing requirements for 2026 come down to one final rule that took effect June 10, 2026, plus a set of notices that confirm the status quo. There was no new drug added to the DOT panel, no change to FMCSA's random rates, and oral fluid testing still is not available.

Below is every item we could tie to a dated federal document, oldest first, and then what is still only a proposal. As of November 1, 2026.

This page summarizes federal documents in plain language. It is not legal advice. Confirm how a change applies to your program with your own counsel or your C/TPA.

2026 at a glance

The one new rule: directly observed urine collections (effective June 10, 2026)

On May 11, 2026, DOT published a final rule amending 49 CFR Part 40 (91 FR 25507). It took effect June 10, 2026.

The problem it fixes. DOT's May 2023 rule (88 FR 27596) allowed oral fluid testing and, in a few situations, required a directly observed collection to be an oral fluid test. But oral fluid testing needs at least two HHS-listed oral fluid laboratories, and the 2026 rule states that, as of its publication, there were none. So that requirement could not be met.

What the rule does. Until oral fluid testing is available, the required observed collection is a directly observed urine collection. In the rule's words, it requires "a directly observed urine collection in situations where oral fluid tests are currently required but cannot be conducted because oral fluid testing is not yet available."

Specifically, under the amended 49 CFR 40.67(g):

• If oral fluid is not yet available and no same-sex observer is at the collection site, the collector contacts the employer's DER, who either arranges a same-sex observer or sends the employee to another site for a directly observed urine collection.
• Once oral fluid is available and no same-sex observer can be found, the collector follows the employer's standing order, or the DER directs an oral fluid test.
• After HHS gives notice of a second oral fluid laboratory, there is an 18-month grace period during which employers can keep using directly observed urine collections while they set up oral fluid. DOT proposed one year and extended it to 18 months after comments. ODAPC will publish a Federal Register notice when that period starts and ends.

Two smaller changes in the same rule:

• A new 40.65(d): when a temperature or tampering problem calls for a new collection, the collector checks whether the employer has a standing order on which specimen type to use, and if not, contacts the DER.
• The word "gender" was replaced with "sex" in 40.67, 40.69 and 40.145.

DOT itself says the rule applies only in "very rare cases" and does not expect it to raise testing costs.

What to do: if you have no standing order on specimen type for observed collections, decide on one and give it to your collector and C/TPA.

Random testing rates for 2026: unchanged

The baseline in 49 CFR 382.305(b) is 50% of average driver positions for drugs and 10% for alcohol. FMCSA changes a rate only by publishing the new one in the Federal Register (382.305(c) and (f)).

DOT announced on January 8, 2026 that FMCSA's rates stay at 50% and 10% for 2026, as reported by Trucksafe (Rob Carpenter, January 13, 2026). We found no FMCSA rate notice in the Federal Register for 2026, which matches an unchanged rate.

Other DOT agencies publish their own rates. FAA (December 5, 2025), PHMSA (December 9, 2025) and FRA (January 8, 2026) each published a 2026 random rate notice in the Federal Register. Check your own agency's notice if you are not FMCSA-regulated. More: DOT random drug testing requirements.

SAP and return-to-duty: a formal reminder (March 4, 2026)

On March 4, 2026, DOT published a notification on the Substance Abuse Professional and return-to-duty process (91 FR 10518). It does not change the rule text. It reminds SAPs to follow Part 40 and reminds employers of what SAPs are supposed to do.

DOT listed the problems that prompted it, including:

• Employers having trouble getting follow-up testing plans from SAPs
• SAPs referring employees only to online programs when in-person programs were appropriate
• SAPs prescribing the minimum number of follow-up tests under pressure from C/TPAs
• SAPs administering follow-up tests themselves
• People acting as SAPs without the right credential
• Remote evaluations without real-time two-way audio and video

If you have a driver in return-to-duty, make sure you hold the SAP's follow-up testing plan. See our return-to-duty testing page.

Fentanyl: in the HHS federal panel, not in the DOT panel

HHS's drug panel for federal agency employees includes fentanyl and norfentanyl. On March 13, 2026, HHS confirmed it made "no revisions to the current drug testing panels" (91 FR 12308).

That HHS panel governs federal agency programs. DOT's panel is in its own rule. As published on eCFR for October 1, 2026, 49 CFR 40.82 still lists five classes, the 40.85 cutoff table has no fentanyl row, and a laboratory "must not test 'DOT specimens' for any other drugs." We found no DOT rule adding fentanyl. If one is published, this page will be updated.

Current DOT cutoffs: DOT drug test cutoff levels.

Oral fluid: allowed on paper, still not available

The HHS laboratory lists dated September 30, 2026 (91 FR 61854) and November 2, 2026 (91 FR 68964) both state that, at this time, no laboratory is approved by HHS to run drug and specimen validity tests on oral fluid specimens.

Until there are two, DOT testing is urine. Full explainer: oral fluid testing under 49 CFR Part 40.

Still pending: proposals, not rules

Petition on invalid specimens (October 1, 2026). DOT published notice of a petition, received February 27, 2026, asking it to amend Part 40 on how MROs handle medical explanations for abnormal validity results, including pH, and for inability to provide a specimen under direct observation. Comments were open until November 2, 2026 (91 FR 62409). DOT has not decided whether to grant it.

HHS guideline revisions (October 29, 2026). HHS proposed revisions to its urine guidelines and oral fluid guidelines (91 FR 68398 and 91 FR 68364). For urine, the proposals include raising the pH cutoff for an invalid result from 9.0 to 9.5 and letting an MRO authorize a biomarker test for certain invalid results. Comments are due December 28, 2026. These are federal agency guidelines; DOT laboratories must also follow applicable HHS requirements (49 CFR 40.81(c)), so watch for the final version.

Quick answers

Did the DOT drug test panel change in 2026?

No. The five classes in 40.82 and the cutoffs in 40.85 are unchanged.

Can my company switch to mouth swab DOT tests in 2026?

Not yet. There are no HHS-listed oral fluid laboratories as of the November 2, 2026 list.

Did FMCSA change random testing rates for 2026?

No. 50% drugs, 10% alcohol.

Is there anything I need to do because of the June 2026 rule?

Give your collector a standing order on specimen type for observed collections, so a missing observer does not stall a test.

Stay current without tracking the Federal Register

BBB Mobile DOT Drug Testing collects DOT tests on site across Park City, Summit and Wasatch counties and the Salt Lake metro, and runs a Utah DOT random testing consortium. Background reading: DOT drug testing requirements for Utah employers and the FMCSA Clearinghouse guide. Price a visit with the estimator or call (435) 395-1459.